JP7698577B2 - 組織常在メモリー様ｔ細胞を生成するための方法及びその使用 - Google Patents

組織常在メモリー様ｔ細胞を生成するための方法及びその使用 Download PDF

Info

Publication number
JP7698577B2
JP7698577B2 JP2021521143A JP2021521143A JP7698577B2 JP 7698577 B2 JP7698577 B2 JP 7698577B2 JP 2021521143 A JP2021521143 A JP 2021521143A JP 2021521143 A JP2021521143 A JP 2021521143A JP 7698577 B2 JP7698577 B2 JP 7698577B2
Authority
JP
Japan
Prior art keywords
cells
trm
expression
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521143A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020081987A5 (https=
JP2022505194A (ja
JP2022505194A5 (https=
Inventor
カッシアン イー
ファーラー ハサン
Original Assignee
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム filed Critical ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム
Publication of JP2022505194A publication Critical patent/JP2022505194A/ja
Publication of JPWO2020081987A5 publication Critical patent/JPWO2020081987A5/ja
Publication of JP2022505194A5 publication Critical patent/JP2022505194A5/ja
Priority to JP2025018950A priority Critical patent/JP2025084776A/ja
Application granted granted Critical
Publication of JP7698577B2 publication Critical patent/JP7698577B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021521143A 2018-10-18 2019-10-18 組織常在メモリー様ｔ細胞を生成するための方法及びその使用 Active JP7698577B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025018950A JP2025084776A (ja) 2018-10-18 2025-02-07 組織常在メモリー様ｔ細胞を生成するための方法及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862747523P 2018-10-18 2018-10-18
US62/747,523 2018-10-18
US201962846270P 2019-05-10 2019-05-10
US62/846,270 2019-05-10
PCT/US2019/057016 WO2020081987A1 (en) 2018-10-18 2019-10-18 Methods for production of tissue resident memory-like t cells and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025018950A Division JP2025084776A (ja) 2018-10-18 2025-02-07 組織常在メモリー様ｔ細胞を生成するための方法及びその使用

Publications (4)

Publication Number Publication Date
JP2022505194A JP2022505194A (ja) 2022-01-14
JPWO2020081987A5 JPWO2020081987A5 (https=) 2022-10-21
JP2022505194A5 JP2022505194A5 (https=) 2022-10-21
JP7698577B2 true JP7698577B2 (ja) 2025-06-25

Family

ID=70284129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521143A Active JP7698577B2 (ja) 2018-10-18 2019-10-18 組織常在メモリー様ｔ細胞を生成するための方法及びその使用
JP2025018950A Withdrawn JP2025084776A (ja) 2018-10-18 2025-02-07 組織常在メモリー様ｔ細胞を生成するための方法及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025018950A Withdrawn JP2025084776A (ja) 2018-10-18 2025-02-07 組織常在メモリー様ｔ細胞を生成するための方法及びその使用

Country Status (7)

Country Link
US (2) US12319740B2 (https=)
EP (1) EP3866814A4 (https=)
JP (2) JP7698577B2 (https=)
KR (1) KR20210078518A (https=)
CN (1) CN113056276A (https=)
CA (1) CA3115487A1 (https=)
WO (1) WO2020081987A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
GB202007321D0 (en) * 2020-05-18 2020-07-01 Inst De Medicina Molecular Joaeo Lobo Antunes T cells
CN111944749A (zh) * 2020-08-14 2020-11-17 福建医科大学附属协和医院 一种用于治疗心肌梗死的人脂肪间充质干细胞外泌体的制备方法
CN112516141A (zh) * 2020-12-07 2021-03-19 浙江大学 Cd47表达抑制剂及其与免疫治疗药物联合使用
US20240368545A1 (en) * 2021-05-07 2024-11-07 Yasuhito TOKUMOTO Manufacturing method of memory t cells
US20250281539A1 (en) * 2022-05-10 2025-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of culturing tumor infiltrating lymphocytes
CN115975921B (zh) * 2022-12-09 2025-12-19 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种体外诱导组织驻留性记忆cd8+t细胞的方法
WO2024253594A1 (en) * 2023-06-07 2024-12-12 Agency For Science, Technology And Research Small molecule based method of modifying t cells
WO2025076124A1 (en) * 2023-10-02 2025-04-10 Immunitybio, Inc. Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
WO2025096644A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
WO2025129119A1 (en) * 2023-12-15 2025-06-19 La Jolla Institute For Immunology Gpr25 agonization for cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228839A1 (en) 2015-07-20 2018-08-16 Mayo Foundation For Medical Education And Research Methods and materials for producing t cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
WO2017079113A1 (en) 2015-11-02 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Healh And Human Services Methods of producing t cell populations using prolyl hydroxylase domain-containing protein inhibitors
US20200078401A1 (en) 2016-12-07 2020-03-12 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US20240197782A1 (en) * 2021-04-20 2024-06-20 Board Of Regents, The University Of Texas System Methods and compositions for genetic modification and therapeutic use of immune cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228839A1 (en) 2015-07-20 2018-08-16 Mayo Foundation For Medical Education And Research Methods and materials for producing t cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOMBRINK, P., et al.，"Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells."，NATURE IMMUNOLOGY，2016年11月28日，Vol.17, No.12，pp.1467-1478，DOI: 10.1038/ni.3589
MA, C., et al.，"TGF-beta controls the formation of kidney-resident T cells via promoting effector T cell extravasation."，THE JOURNAL OF IMMUNOLOGY，2017年01月15日，Vol.198, No.2，pp.749-756，DOI: 10.4049/jimmunol.1601500
NIZARD, M., et al.，"Induction of resident memory T cells enhances the efficacy of cancer vaccine."，NATURE COMMUNICATIONS，2017年05月24日，Vol.8，15221 (pp.1-11)，DOI: 10.1038/ncomms15221
ZAID, A., et al.，"Chemokine receptor-dependent control of skin tissue-resident memoty T cell formation."，THE JOURNAL OF IMMUNOLOGY，2017年10月01日，Vol.199, No.7，pp.2451-2459，DOI: 10.4049/jimmunol.1700571

Also Published As

Publication number Publication date
KR20210078518A (ko) 2021-06-28
CA3115487A1 (en) 2020-04-23
EP3866814A4 (en) 2022-07-27
US20250320306A1 (en) 2025-10-16
CN113056276A (zh) 2021-06-29
US12319740B2 (en) 2025-06-03
EP3866814A1 (en) 2021-08-25
US20210355443A1 (en) 2021-11-18
WO2020081987A1 (en) 2020-04-23
JP2025084776A (ja) 2025-06-03
JP2022505194A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
JP7698577B2 (ja) 組織常在メモリー様ｔ細胞を生成するための方法及びその使用
EP3525803B1 (en) Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US20240016840A1 (en) Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
JP2024123210A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
US20190119350A1 (en) Ny-eso-1 specific tcrs and methods of use thereof
JP7447011B2 (ja) エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用
KR20200133370A (ko) 입양 주입된 t 세포의 지속성 강화 방법
CA3205637A1 (en) Treatment of cancer with nk cells and a cd20 targeted antibody
JP2024534767A (ja) キメラ抗原受容体がん免疫療法の有効性を増強するためのＢｃｌ－２の調節
US20240018474A1 (en) Modulating bhlhe40 in the differentiation of type 1 regulatory t cells and controlling t cell exhaustion
WO2025029648A1 (en) Compositions and methods for targeting loxhd1-associated disease
RU2775674C2 (ru) Способы иммунотерапии и композиции, включающие модуляторы метаболического пути триптофана
WO2024148212A2 (en) T cell receptors directed to sox2 protein
WO2025008798A1 (en) Compositions and methods for culturing t cells
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法
HK40013225B (en) Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
HK40013225A (en) Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250613

R150 Certificate of patent or registration of utility model

Ref document number: 7698577

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150